Forecast

The analysts' average price target is €175.31 (+31.79%). The median is €177.80 (+33.66%).

Buy	32
Hold	5
Sell	0

News Go to news feed

Neurocrine Biosciences under pressure after safety concerns about Vykat XR

Neurocrine shares fell after a joint statement by three patient organizations raised safety concerns about Vykat XR, citing reports to the FDA of seven deaths and more than 100 serious adverse events. The groups did not call for a market withdrawal and did not establish causality; CEO Kyle Gano nevertheless rejected a link. Additional pressure comes from worries about price risks for INGREZZA, even though Neurocrine reported strong operational data, including record Q2 2026 sales and positive phase‑4 results for INGREZZA; the stock is likely to remain under short‑term pressure until regulators and investors gain more clarity. » More on de.investing.com
Safety reports on Vykat weigh on Neurocrine Biosciences stock

Neurocrine Biosciences shares fell sharply after reports of several deaths and more than 100 serious adverse events linked to the Prader‑Willi drug Vykat were published. Doctors and experts reported incidents to Stat News but noted that no clear causal link to Vykat has been proven and no withdrawal has been requested. CEO Kyle Gano said the company sees no connection but did not rule out changes to the label or instructions for physicians. At the same time, Neurocrine reported positive phase‑4 data for Ingrezza in tardive dyskinesia with no new safety concerns. » More on de.investing.com
Neurocrine starts phase‑1 study for triple agonist NBIP-1968 against obesity

Neurocrine has begun a phase‑1 clinical study of NBIP-1968, a long‑acting triple agonist (GLP‑1, GIP, glucagon) for the treatment of obesity. The study will assess the safety and tolerability of single ascending doses in adult participants across different BMI categories, including overweight and obesity. NBIP-1968 is designed for once‑weekly subcutaneous administration and is planned to be developed in a fixed dose combination with NBIP-2118. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Neurocrine Biosciences has already paid €0.26 in dividends. The last payout was in March 2022.

Financials

In the last quarter, Neurocrine Biosciences had revenue of €840.29M and net profit of €126.52M

(EUR)	Jun 2026	YoY
Revenue	840.29M	44.06%
Gross profit	819.96M	42.92%
Net profit	126.52M	38.73%
EBITDA	166.39M	17.58%

Fundamentals

Metric	Value
Market capitalization	€13.37B
Number of shares	100.55M
52-week high/low	€160.64 - €105.42
Dividends	No
Beta	0.39
P/E ratio	21.85
PEG ratio	0.21
P/B ratio	4.21
P/S ratio	4.59

Company profile

Neurocrine Biosciences, Inc. erforscht, entwickelt und vermarktet Arzneimittel für neurologische, endokrine und psychiatrische Erkrankungen. Das Portfolio des Unternehmens umfasst Behandlungen für Spätdyskinesien, die Parkinson-Krankheit, Endometriose und Uterusmyome sowie klinische Programme in verschiedenen Therapiebereichen. Das führende Produkt ist INGREZZA, ein VMAT2-Inhibitor zur Behandlung von Spätdyskinesien. Zu den kommerziellen Produkten des Unternehmens gehören ONGENTYS, ein Katechol-O-Methyltransferase-Hemmer, der als Zusatztherapie zu Levodopa/DOPA-Decarboxylase-Hemmern bei Parkinson-Patienten eingesetzt wird, ORILISSA für die Behandlung von mäßigen bis starken Endometrioseschmerzen bei Frauen und ORIAHNN, eine nicht-chirurgische orale Medikamentenoption für die Behandlung von starken Menstruationsblutungen im Zusammenhang mit Uterusmyomen bei Frauen vor der Menopause. Zu den Produktkandidaten des Unternehmens in der klinischen Entwicklung gehören NBI-921352 zur Behandlung pädiatrischer Patienten sowie erwachsener fokaler Epilepsie-Indikationen und NBI-827104 zur Behandlung seltener pädiatrischer Epilepsie und essentiellen Tremors. Zu den Produkten des Unternehmens in der klinischen Entwicklung gehören auch NBI-1065845 zur Behandlung von schweren depressiven Störungen, NBI-1065846 zur Behandlung von Anhedonie bei schweren depressiven Störungen und NBI-118568 zur Behandlung von Schizophrenie. Es hat Lizenz- und Kooperationsvereinbarungen mit Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc, Voyager Therapeutics, Inc, BIAL - Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation und AbbVie Inc. Neurocrine Biosciences, Inc. wurde 1992 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.

Name	Neurocrine Biosciences
CEO	Kyle W. Gano
Headquarters	San Diego, ca USA
Website	neurocrine.com
Sector	Health Care
Industry	Biotechnology
IPO	05/23/1996
Employees	2,500